Öz

Objective: During the pandemic, molnupiravir and favipiravir treatments have been applied at different stages of the treatment of COVID-19 patients. However, their effectiveness in COVID-19 patients admitted to the ICU is not clear.

Methods: Patients who were admitted to the ICU between March 1, 2022, and December 31, 2023 and managed according to the guidelines of the Scientific Committee of the Turkish Ministry of Health were included.

Results: Data of 152 patients who met the inclusion criteria for the study were evaluated. Patients were divided into two groups according to the treatment modality applied. When both groups were compared in terms of median hospital stay; It was found to be statistically significant (p=0.025) in Group F and 16 (11) days in Group M. When respiratory support was examined in the entire cohort; the percentage of invasive mechanical ventilation application was found to be significant as 40 (60.5) in Group F and 61 (80.3) in Group M (p=0.008). Similarly, the number of days of invasive mechanical ventilation was found to be significant as 9 (14) in Group F and 12 (8) in Group M (p=0.010). On the other hand, when evaluated in terms of hospital mortality percentage; it was found to be 42 (55.3) in Group F and 39 (51.3) in Group M and no statistically significant difference was found (p=0.626).

Conclusion: In our study, no difference was found in terms of mortality rate between molnupiravir and favipiravir, two antiviral drugs used in COVID-19 treatment. However, further studies are needed to clarify this issue.

Anahtar Kelimeler: intensive care unit, COVID-19, anti-viral drugs, mortality rate

Referanslar

  1. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19:155-70. https://doi.org/10.1038/s41579-020-00468-6
  2. Attwood SW, Hill SC, Aanensen DM, Connor TR, Pybus OG. Phylogenetic and phylodynamic approaches to understanding and combating the early SARS-CoV-2 pandemic. Nat Rev Genet. 2022;23:547-62. https://doi.org/10.1038/s41576-022-00483-8
  3. World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. WHO; 2019. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
  4. T.C. Sağlık Bakanlığı. Genel koronavirüs tablosu. Ankara: T.C. Sağlık Bakanlığı; 2022. Available at: https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html
  5. Öner Ö, Ergan B, Gürkök MÇ, et al. Is there a relationship between mortality rates and nutritional factors in critical ill patients with COVID-19? Turk J Intensive Care. 2023;21:74-82. https://doi.org/10.4274/tybd.galenos.2022.92905
  6. Mali KR, Eerike M, Raj GM, et al. Efficacy and safety of molnupiravir in COVID-19 patients: a systematic review. Ir J Med Sci. 2023;192:1665-78. https://doi.org/10.1007/s11845-022-03139-y
  7. Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: a systematic review of literature. Diabetes Metab Syndr. 2021;15:102329. https://doi.org/10.1016/j.dsx.2021.102329
  8. T.C. Sağlık Bakanlığı. Ağır pnömoni, ARDS, sepsis ve septik şok yönetimi. Ankara: T.C. Sağlık Bakanlığı; 2025. Available at: https://covid19.saglik.gov.tr/TR-66340/agir-pnomoni-ards-sepsis-ve-septik-sok-yonetimi.html
  9. Yasri S, Wiwanitki V. Molnupiravir, favipiravir and other antiviral drugs with proposed potentials for management of COVID-19: a concern on antioxidant aspect. Int J Biochem Mol Biol. 2022;13:1-4.
  10. Ghasemnejad-Berenji M, Pashapour S. Favipiravir and COVID-19: a simplified summary. Drug Res (Stuttg). 2021;71:166-70. https://doi.org/10.1055/a-1296-7935
  11. Tian L, Pang Z, Li M, et al. Molnupiravir and its antiviral activity against COVID-19. Front Immunol. 2022;13:855496. https://doi.org/10.3389/fimmu.2022.855496
  12. Agostini ML, Pruijssers AJ, Chappell JD, et al. Small-molecule antiviral β-d-N4-Hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93:e01348-19. https://doi.org/10.1128/JVI.01348-19
  13. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53:436-43. https://doi.org/10.1016/j.jmii.2020.03.034
  14. Babayigit C, Kokturk N, Kul S, et al. The association of antiviral drugs with COVID-19 morbidity: the retrospective analysis of a nationwide COVID-19 cohort. Front Med (Lausanne). 2022;9:894126. https://doi.org/10.3389/fmed.2022.894126
  15. Panda PK, Bandyopadhyay A, Singh BC, et al. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21:866. https://doi.org/10.1186/s13063-020-04774-5
  16. Wen W, Chen C, Tang J, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54:516-23. https://doi.org/10.1080/07853890.2022.2034936
  17. Korula P, Alexander H, John JS, et al. Favipiravir for treating COVID-19. Cochrane Database Syst Rev. 2024;2:CD015219. https://doi.org/10.1002/14651858.CD015219.pub2
  18. WHO Solidarity Trial Consortium , Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021;384:497-511. https://doi.org/10.1056/NEJMoa2023184
  19. Eloy P, Le Grand R, Malvy D, Guedj J. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: one + zero equals two? EBioMedicine. 2021;74:103663. https://doi.org/10.1016/j.ebiom.2021.103663
  20. Amani B, Khanijahani A, Amani B, Hashemi P. Lopinavir/ritonavir for COVID-19: a systematic review and meta-analysis. J Pharm Pharm Sci. 2021;24:246-57. https://doi.org/10.18433/jpps31668
  21. Özlüşen B, Kozan Ş, Akcan RE, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis. 2021;40:2575-83. https://doi.org/10.1007/s10096-021-04307-1
  22. Guner AE, Surmeli A, Kural K, et al. ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol. North Clin Istanb. 2021;8:119-23. https://doi.org/10.14744/nci.2021.60420
  23. Guan Y, Puenpatom A, Johnson MG, et al. Impact of molnupiravir treatment on patient-reported COVID-19 symptoms in the phase 3 MOVe-OUT trial: a randomized, placebo-controlled trial. Clin Infect Dis. 2023;77:1521-30. https://doi.org/10.1093/cid/ciad409
  24. Karniadakis I, Mazonakis N, Tsioutis C, Papadakis M, Markaki I, Spernovasilis N. Oral molnupiravir and nirmatrelvir/ritonavir for the treatment of COVID-19: a literature review with a focus on real-world evidence. Infect Dis Rep. 2023;15:662-78. https://doi.org/10.3390/idr15060061
  25. Kamal L, Ramadan A, Farraj S, Bahig L, Ezzat S. The pill of recovery; molnupiravir for treatment of COVID-19 patients; a systematic review. Saudi Pharm J. 2022;30:508-18. https://doi.org/10.1016/j.jsps.2022.03.002

Telif hakkı ve lisans

Telif hakkı © 2026 Yazar(lar). Açık erişimli bu makale, orijinal çalışmaya uygun şekilde atıfta bulunulması koşuluyla, herhangi bir ortamda veya formatta sınırsız kullanım, dağıtım ve çoğaltmaya izin veren Creative Commons Attribution License (CC BY) altında dağıtılmıştır.

Nasıl atıf yapılır?

1.
Öner Ö, Avkan Oğuz V, Gürkok MÇ, Yakar MN, Ergan B, Hancı V, et al. Retrospective analysis of the efficacy of molnupiravir and favipiravir in COVID-19 patients admitted to intensive care unit. Turk J Intensive Care. 2026;24(1):30-39. https://doi.org/10.63729/TJIC.2026.686